The invention relates methods of determining therapeutic doses for conditions mediated by integrin and methods of therapy for conditions mediated by integrin comprising administering an integrin modulating compound in an amount that achieves receptor occupancy of the integrin. The invention further relates to dosage forms for daily administration of integrin modulating compounds that are useful for treating conditions mediated by at least one integrin including, e.g., fibrosis such as idiopathic pulmonary fibrosis (IFF) and nonspecific interstitial pneumonia (NSIP).

The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.

The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related diseases involving detection of the PRO52254 polypeptide.

The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related diseases involving detection of the PRO52254 polypeptide.

The invention relates generally to variant activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these variant anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

The present invention relates to anti-IL-36R binding compounds, in particular new anti-IL-36R antibodies and therapeutic and diagnostic methods and compositions for using the same.

Contemplated test panels, test kits, and methods using same for food sensitivity in subjects with eczema.

The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related diseases involving detection of the PRO52254 polypeptide.

The present invention relates to methods of detecting Anti-Drug Antibodies. The present invention also relates to methods of monitoring patients undergoing therapeutic antibody treatment. The invention further relates to kits suitable for the implementation of the above methods.

Antibodies against the human sodium channel Nav 1.9 are described. Also described, is the use of such antibodies in the diagnosis of inflammatory skin diseases. A process for preparing antibodies directed against the human Nav 1.9 is also described.